Cullinan Therapeutics, Inc. CGEM R2KR3KPHARMA
Company Overview
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +189.14% |
| 6 Months: | +40.34% |
| 3 Months: | +63.51% |
| 1 Month: | +23.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.76 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGEM Cullinan Therapeutics, Inc. R2KR3KPHARMA | 22.09 | -7.10 | $1.42B | 0.00% | -58.85% | -53.80% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 18.94M | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -5.54M | -14.12M | -11.50M | 1.37M | -16.60M | -18.38M | -32.66M | 239.68M | -29.77M | -62.76M | -37.60M | -45.24M | -42.99M | -50.03M | -48.85M | -55.00M | -75.80M | -55.59M | -53.70M | -57.25M |
| Net Income | -4.97M | -8.62M | -9.86M | -70.00K | -15.64M | -17.35M | -12.10M | 174.90M | -24.80M | -57.96M | -32.21M | -39.18M | -37.15M | -42.03M | -40.56M | -48.50M | -70.06M | -50.61M | - | - |
| Diluted EPS | - | - | - | - | -0.36 | -0.40 | -0.27 | 3.77 | -0.54 | -1.42 | -0.82 | -0.91 | -0.86 | -0.75 | -0.69 | - | - | - | - | - |
| R&D Expense | 4.17M | 12.50M | 9.91M | 12.41M | 11.78M | 12.68M | 24.54M | 26.41M | 19.68M | 52.10M | 27.39M | 33.82M | 30.65M | 36.26M | 35.51M | 41.46M | 61.03M | 41.97M | 42.12M | 44.44M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 132.14M | 190.65M | 196.92M | 241.65M |
| Operating Income | -60.34M | - | -132.14M | -190.65M | -196.92M | -241.65M |
| EBITDA | - | - | -132.04M | -190.34M | -196.61M | -241.34M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | 151.32M | -169.22M | -167.46M | -219.88M |
| Tax Provision | - | - | 42.12M | -14.12M | 117.00K | 0 |
| Net Income | -51.80M | - | 111.21M | -153.16M | -167.38M | -219.88M |
| Diluted EPS | - | - | 2.38 | -3.21 | -2.78 | -3.36 |
| R&D Expense | 43.21M | 57.75M | 91.95M | 148.16M | 142.90M | 187.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 214.71M | 437.19M | 561.12M | 484.18M | 621.82M | 448.37M |
| Total Equity | 97.00M | 199.01M | 424.97M | 535.03M | 453.70M | 590.33M | 408.73M |
| Cash & Equivalents | - | 168.20M | 59.77M | 156.15M | 98.43M | 83.00M | 88.33M |
| Total Liabilities | - | 14.39M | 11.81M | 26.09M | 30.29M | 31.50M | 39.64M |
| Current Liabilities | - | 14.32M | 11.75M | 22.50M | 28.14M | 30.65M | 37.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -29.77M | -43.43M | -126.66M | -134.28M | -145.30M | -175.75M |
| Investing Cash Flow | -5.42M | -333.77M | 248.97M | 35.81M | -136.31M | 179.99M |
| Financing Cash Flow | 140.14M | 268.78M | -25.93M | 40.75M | 266.19M | 1.09M |
| Capital Expenditure | -10.00K | -0 | -1.13M | -208.00K | -0 | -49.00K |
| Free Cash Flow | -29.78M | -43.43M | -127.80M | -134.48M | -145.30M | -175.80M |
| Share Buybacks | 6.57M | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -26.0% | - | 20.8% | -33.8% | -28.4% | -53.8% |
| ROCE % | -30.1% | - | -24.5% | -41.8% | -33.3% | -58.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | MPM Bioimpact LLC | 15.12% | 9.73M | $211.17M |
| 2 | Lynx1 Capital Management Lp | 13.93% | 8.96M | $194.51M |
| 3 | BVF Inc. | 8.94% | 5.75M | $124.79M |
| 4 | Blackrock Inc. | 8.13% | 5.23M | $113.55M |
| 5 | Price (T.Rowe) Associates Inc | 5.95% | 3.83M | $83.02M |
| 6 | State Street Corporation | 5.70% | 3.67M | $79.61M |
| 7 | Kynam Capital Management, LP | 4.84% | 3.11M | $67.58M |
| 8 | Vanguard Capital Management LLC | 4.06% | 2.61M | $56.73M |
| 9 | RTW Investments LP | 3.67% | 2.36M | $51.31M |
| 10 | Siren, L.L.C. | 2.94% | 1.89M | $41.09M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CGEM
171,031 Shares in Cullinan Therapeutics, Inc. $CGEM Bought by Bank of New York Mellon Corp - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxOVXo0bDNrOC13a0JZMDY2MGNoYy1OWmhWcEQtei1IQVZDOC1jUXk0ZlUyOG11cDBHbW1yZVpqem5pZ09fUk44QXJaRnNON1N5Nk1wNGxsV01qRmpWUFJLREtFa2pfcGN0LUlMOXNIRWNmQTVabnVsWlhRWFRwVXhGYkc3STVMTnJkc2Y1NE…
Why Cullinan Therapeutics (CGEM) Is Up 6.6% After Zipalertinib’s Positive Phase 3 Lung Cancer Data And What's Next - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOYWtmRVNwSnJudnZ5ZF9XVTlTcU8tc1V3a25CNkNGajB3REhYZ0RFVEg4ZDdLU292VlZ3QkJnZEJwS3ktN3dwSC0ycXVkTUljd0J1RDZsMU9tODFNc2J5d3pRWkZVY0lSWm5qcWQwT1c2Z0pYVHRENUZ0TzZpSGpaNVJIWl9GQ3pEMDBqd2…
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxPcDRUdlM2aWdKaFhkU1RWQXo0YmlBN3BpY202dVVKYnpiZ1FwTk1nZW5wNlFVNHNhemxtM0w3Zkh5b1cxZ3NHMUdvY1pXQ0RFTHdHT1NwbDU5MTZQMmVGVmFjczRZY0NDb1NlWE1rVmt0cUN1Wms0OTdRNzM2VjJMUGNZZWQxWVhUZFpxN1…
Cullinan to begin potentially registrational acute myeloid leukemia study in Q3 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPa3hxbUlScmZiNUdCNUtTTTdJZEtzN3lHSE5xWl9maUVxTFFoTzlocUIxeWx0LW9zNUFJYnU2X3hVQXFEcmc2aGlmUURyVTlSaEd1ckVRSF9iT3BQbzRsSWNmbFNiRFJqNzdrTmtNM1U1TXR2djE3NUdscHZkdkE5dUk3cWs4YzR5OWhBWV…
Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset (NASDAQ:CGEM) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPaC12YWJxVWJUaDdyOVFNSHJSSHZRQmExaUlEOFVvYTFJYmJkMTJ5SDF6VlBNT0lxbllGRG0wQjNETERJUWEzRXBnNzNfTTlFb3N4bUxITFVCd0l0QUp4UVR3T3RCckREMmlYQnNlT1BPYjA2dHR6ZnFEbEh6Z3kxOXdyOU9JYXRLb2xCRG…
CGEM Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5kQk5aU0pPZlFERVV6TEluN1BEODBmazh3aS1vQW5rWEl0Y1lKWjF0RzgyUzRQdXZBa2hFMnktcl9yWU1mRmlfazNMY1pLY3QyYTRoVU1rT0dKaEt4Ui1ra0hLS2YxMnh0d0ZCWmZMMVdpM2ZpZjQ0Y09n?oc=5" target="_blank">CGE…
CGEM — Frequently Asked Questions
What is the current share price of Cullinan Therapeutics, Inc. (CGEM)?
As of 2026-09-07 16:24 PDT, Cullinan Therapeutics, Inc. (CGEM) trades at $22.09 on NasdaqGS. Its 52-week range is $5.75 to $22.95.
What is the market capitalisation of CGEM?
Cullinan Therapeutics, Inc. (CGEM) has a market capitalisation of $1.42B on NasdaqGS.
What is the P/E ratio of CGEM?
CGEM trades at a trailing price-to-earnings (P/E) ratio of -7.10. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.61.
What is the return on equity (ROE) of CGEM?
CGEM has a return on equity (ROE) of -53.80%. Its return on capital employed (ROCE) is -58.85%.
Is CGEM a good stock to buy?
This page provides a data-driven analysis of Cullinan Therapeutics, Inc. (CGEM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.